Ophthalmology business Acquired by Axol Bioscience — Healthcare M&A

Axol Bioscience, a Cambridge, UK-based strategic buyer focused on human induced pluripotent stem cell (iPSC) technologies, has acquired the ophthalmology business of Newcells Biotech in an add-on deal. The transaction covers Newcells’ ophthalmology team, facilities and intellectual property, with the purchase price undisclosed. The acquired portfolio includes retinal organoid and retinal pigment epithelium (RPE) models used for drug discovery and safety testing, supporting iPSC-derived preclinical research and translational development services for biopharma and contract research organizations (CROs) across Europe and the US.

The acquisition strengthens Axol’s position in healthcare and ophthalmology drug discovery by expanding its suite of human-relevant disease models. Newcells, a spinout from Newcastle University, develops in vitro tools designed to help drug developers assess how therapies interact with tissues, including applications for evaluating gene therapy viral vectors and investigating disease mechanisms, efficacy and safety. The move also aligns with broader market demand for predictive, human-based models that can help de-risk programs earlier in the development pipeline.

While financial terms were not disclosed, the deal is positioned as a platform integration: Axol plans to combine Newcells’ retinal organoid capabilities with its existing ophthalmology portfolio to broaden its offering of iPSC-derived retinal models. The transaction follows Axol’s recent expansion in ophthalmology and dermatology through prior acquisitions, including Phenocell, and further extends its strategy to grow beyond neuroscience and into additional therapeutic areas.